Related Experiment Video
Updated: Dec 30, 2025

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Severe fingolimod rebound syndrome after switching to cladribine treatment
Fernanda Coss-Rovirosa1, Jorge Salado-Burbano1, Adriana Casallas-Vanegas2
1The American British Cowdray Medical Center, Mexico City, Mexico.
Abstract:
We present the clinical and imaging characteristics of a patient whom presented with rebound syndrome after switching from fingolimod to cladribine treatment due to hematologic toxicity. Previous imaging studies had shown a non-aggressive phenotype of the disease, however multiple active tumefactive lesions became evident after beginning treatment with cladribine. The patient responded well to plasmapheresis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Desensitization and Tachyphylaxis
Clot Retraction and Fibrinolysis
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
